KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Total Liabilities (2017 - 2025)

Twist Bioscience (TWST) has disclosed Total Liabilities for 7 consecutive years, with $152.8 million as the latest value for Q2 2023.

  • On a quarterly basis, Total Liabilities rose 118.62% to $152.8 million in Q2 2023 year-over-year; TTM through Jun 2023 was $152.8 million, a 118.62% increase, with the full-year FY2022 number at $172.0 million, up 41.82% from a year prior.
  • Total Liabilities was $152.8 million for Q2 2023 at Twist Bioscience, up from $150.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $172.0 million in Q3 2022 to a low of -$820.7 million in Q2 2022.
  • A 5-year average of $39.1 million and a median of $62.9 million in 2020 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 2627.42% in 2022; the steepest drop was 814.56% in 2022.
  • Twist Bioscience's Total Liabilities stood at $89.2 million in 2019, then crashed by 30.92% to $61.6 million in 2020, then tumbled by 90.26% to $6.0 million in 2021, then soared by 2627.42% to $163.6 million in 2022, then decreased by 6.64% to $152.8 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Total Liabilities are $152.8 million (Q2 2023), $150.0 million (Q1 2023), and $163.6 million (Q4 2022).